4DMedical has secured more than US$100 million (approximately AU$150 million) in new institutional funding to accelerate its expansion in the United States and advance development of its software-based lung imaging technology.
The capital will be used primarily to scale deployment of the company’s FDA-cleared CT:VQ™ platform across U.S. hospitals and health systems, while increasing investment in research and development. Following the raise, 4DMedical reported a pro forma cash position exceeding US$130 million, strengthening its balance sheet as it expands its U.S. footprint.
CT:VQ™ is a software-as-a-service platform that generates ventilation and perfusion insights from standard CT scans. Within four months of receiving FDA clearance, the technology was adopted by several leading U.S. academic medical centers, including Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health, signaling early clinical demand for functional lung imaging tools that extend beyond traditional diagnostics.
“This investment reflects growing recognition of both our technology leadership and the scale of the opportunity in the U.S. market,” said Andreas Fouras, founder and chief executive officer of 4DMedical. He added that the funding will support wider adoption, faster product development, and deeper partnerships with U.S. health systems.
The company said the funding will support expanded clinical deployments, customer training and support, and continued development of functional lung imaging capabilities. 4DMedical’s software is designed to integrate with existing hospital infrastructure and imaging workflows, supported by partnerships with medical imaging providers including Philips.
Founded in Australia, 4DMedical develops software-based cardiothoracic imaging technologies that combine proprietary algorithms and artificial intelligence to deliver quantitative insights into lung function.
